Adverse effects of immunosuppression after liver transplantation. (October 2021)

• Record Type: Journal Article
• Authors: Noble, Johan; Terrec, Florian; Malvezzi, Paolo; Rostaing, Lionel
• Is Part Of: Best practice & research. Volume 54/55(2021)
• Publication Date: 2021-10
• Subjects: Tacrolimus -- Liver transplantation -- Posttransplant diabetes mellitus -- Hypertension -- Nephrotoxicity; Gastroenterology -- Periodicals; Gastrointestinal system -- Diseases -- Periodicals; Gastrointestinal Diseases; Gastroenterology; Klinische geneeskunde; Gastro-enterologie; Gastroenterology; Gastrointestinal system -- Diseases; Periodicals; 616.33005
• DOI: 10.1016/j.bpg.2021.101762
• Languages: English
• ISSNs: 1521-6918

Abstract

Abstract: After solid organ transplantation the cornerstone of immunosuppression is based on calcineurin inhibitors (CNIs), mostly tacrolimus. However, CNIs have a very narrow therapeutic window. The most important and serious side-effects of CNIs are nephrotoxicity, high blood pressure, post-transplant diabetes mellitus (PTMD), i.e., new-onset diabetes after transplantation (NODAT), dyslipidemia, and modification to the cardiovascular-risk profile. In this review, we will focus on tacrolimus-related toxicities in the setting of liver transplantation.